RxDoctor Payments Data

Rebecca Ellen

Psychiatric/Mental Health · Baltimore, MDNPI 1962740407

Payments from drug & device makers

$2,852in general payments, 2019–2025

Across 103 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$429
  • Otsuka America Pharmaceutical, Inc.$317
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$252
  • Neurocrine Biosciences, Inc.$251
  • Tris Pharma Inc$248
  • Johnson & Johnson$213
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,852 in reported general payments places this provider in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$25,280
Medicare patients
78
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$44,321
RexultiBrexpiprazole17$30,716
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$4,450
Lisdexamfetamine Dimesylate11$4,341
Aripiprazole50$3,271
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$2,449
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,910
Buspirone Hcl103$1,806
Bupropion XlBupropion Hcl42$1,536
Mirtazapine69$1,271
Atomoxetine Hcl12$1,205
Methylphenidate Hcl25$1,015
Escitalopram Oxalate81$994
Duloxetine Hcl39$918
Clonazepam55$870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$429$44,32117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$317$30,71617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →